Signet Therapeutics is a clinical-stage biotech company pioneering the development of first-in-class targeted cancer therapies using organoids and AI. The company has successfully secured nearly $31 million in funding and has been recognized in Forbes Asia 100 to Watch list. The company’s lead pipeline, SIGX1094, has entered Phase I clinical trials as a potential first-in-class targeted therapy for diffuse gastric cancer, a highly aggressive cancer with no approved targeted treatments. In addition to advancing its own pipeline, Signet`s organoid platform is available for external collaborations, providing innovative preclinical drug discovery and development services to biotech and pharmaceutical partners.